Log In
Print this Print this

Remyelinating antibody (rHIgM22)

  Manage Alerts
Collapse Summary General Information
Company Acorda Therapeutics Inc.
DescriptionRecombinant human mAb for promotion of remyelination
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation
Partner Mayo Clinic

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today